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Purpose: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the
overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and
might be a promising target for immunotherapy of this disease.
Experimental design: Firstly, we investigated the expression profiles of human BAP31 (hBAP31) and mouse BAP31
(mBAP31) in human and mouse normal tissues, respectively. The expression level of hBAP31 in human MMs and
mBAP31 in B16 melanoma cells was also analyzed. Then we constructed novel mBAP31 DNA vaccines and tested
there ability to stimulate mBAP31-specific immune responses and antitumor immunity in B16 melanoma-bearing
mice.
Results: For the first time, we found that protein expression of hBAP31 were dramatically upregulated in human
MMs when compared with human normal tissues. Predominant protein expression of mBAP31 was found in mouse
B16 melanoma cells but not in mouse important organs. When mice were immunized with mBAP31 DNA vaccines,
strong cellular response to mBAP31 was observed in the vaccinated mice. CTLs isolated from immunized mice could
effectively kill mBAP31-positive target mouse B16 melanoma tumor cells in vitro and vaccination with mBAP31
DNA vaccines had potent anti-tumor activity in therapeutic model using B16 melanoma cells.
Conclusions: These are the first data supporting a vaccine targeting BAP31 that is capable of inducing effective
immunity against BAP31-expressing MMs and will be applicable to human MMs and hBAP31 DNA vaccine warrants
investigation in human clinical trials.
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Cancer malignancies are among the most life-threatening
diseases worldwide [1]. MM consists approximately 3% of
all cancers and its incidence continues to rise. Although
treated by adequate surgery, the overall survival of MM at
5 years is less than 10%. For disseminated MM, the appro-
priate systemic medical treatment is still controversial
[2,3]. Identification of new tumor antigens expressed in
melanoma and progresses in the molecular biology and
immunotherapy should in the near future translate into
molecular-based therapeutic strategies [4]. Followed the
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unless otherwise stated.novel strategies, cancer immunotherapy has significantly
developed during the last decades and completes the
therapeutic arsenal [5,6]. Human preclinical trials of
immunotherapy based on the newly defined tumor
antigens highly expressed by MMs have now been re-
ported and cast new light on the therapeutic strategies
of the disease [7,8].
BAP31 is an ER chaperon that associates with newly
synthesized integral membrane proteins and controls
their fate. BAP31 is an integral ER-resident membrane
protein and a component of several large protein com-
plexes [9]. In addition to its role as ER chaperon, BAP31
plays an important role in apoptosis. BAP31 could act as
a regulator of procaspase-8 L processing [10] and could
be cleaved by caspase-8 [11,12]. The cleaved BAP31
fragment, p20, is a potent inducer of apoptosis whenis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion is restricted to a minority of cells in normal human
tissues although its RNA transcripts are ubiquitously
expressed [13,14].
For the first time, we found that protein expression of
hBAP31 were dramatically upregulated in human MM
tissues when compared with human normal tissues, with
a total positive rate of 86.5% (122 of 141 cases). And
predominant protein expression of mBAP31 was found
in mouse B16 melanoma cells but not in mouse import-
ant organs. So we hypothesized that BAP31 might be
used as a promising immunotherapy target for MMs. In
this study we constructed mBAP31 DNA vaccines and
lysosome-associated membrane protein (LAMP) was
used to enhance the immune response against mBAP31.
LAMP can target and bind the endosome/lysosome
through the LAMP transmembrane/cytoplasmic domain.
The luminal domain of LAMP is then integrated into
the lysosome. Consequently, one strategy commonly is
to insert the target DNA into LAMP as a LAMP/antigen
chimera and could greatly enhance the immune re-
sponse against a number of antigens [15,16]. When
C57BL/6 mice were immunized with LAMP-mBAP31
chimera DNA vaccine or mBAP31 DNA vaccine, strong
cellular response to mBAP31 was observed and no
autoimmune disorders were observed in the vaccinated
mice. Moreover, CTLs isolated from mBAP31 DNA
vaccine immunized C57BL/6 mice could effectively kill
mBAP31-positive target mouse B16 melanoma tumor
cells in vitro. Furthermore, in a therapeutic model, vac-
cination with mBAP31 DNA vaccine had potent anti-
tumor activity even in the established B16 melanoma.
These are the first data supporting a vaccine targeting
BAP31 that will be applicable to human MMs.Materials and methods
Mice and cell lines
All animal studies were conducted under a protocol ap-
proved by Animal Care Research Advisory Committee
of Fourth Military Medical University and all experi-
ments involving mice were according to the Guidelines
of the Animal Research Ethics Board of Fourth Military
Medical University. All experiments involving mice
were performed under fully anesthetized by inhalation
of a mixture of oxygen with 5% isoflurane, and all
efforts were made to minimize suffering.
Female C57BL/6 (H-2b) mice (8 weeks old) were main-
tained and treated in accordance with recommendations
for the proper use and care of laboratory animals. 293 T,
mouse colon carcinoma cell line CT26 (H-2d) and mouse
melanoma cell line B16 (H-2b) were purchased from
American Type Culture Collection (ATCC) and cultured
according to standard guidelines.IHC staining
Sections were firstly dewaxed and hydrated. Endogenous
peroxidase activity was blocked with methanol containing
3% H2O2 for 10 min, and nonspecific binding was blocked
by normal goat serum (10%) for 10 min. The sections were
then dipped into mAbs specific for human or mouse
BAP31 developed in our lab. Normal mouse IgG was
applied as negative control. After three washes in PBS, the
slices were dipped into biotin-conjugated goat anti-mouse
IgG (promega) for 1 h at room temperature followed by
streptavidin-HRP complex incubation for another 1 h.
Then antibody complexes were visualized by incubation
with DAB chromogen. Sections were counterstained with
Mayer’s hematoxylin for 30 s, dehydrated through gradient
ethanol, cleared in dimethyl benzene, mounted, and exam-
ined using light microscopy.
Small interference RNA
The mammalian expression vector, pSUPER.retro.circular.
stuffer (OligoEngine), was used for expression of siRNA in
B16 cells. The gene-specific insert specifies a 19-nucleotide
sequence (ggtgaacctccagaacaat) corresponding to nu-
cleotides 339–357 downstream of the transcription start
site of mBAP31, which is separated by a 9-nucleotide non-
complementary spacer (tctcttgaa) from the reverse com-
plement of the same 19-nucleotide sequence. This vector
was referred to as pSUPER-mBAP31. A control vector
(pSUPER-Control) was constructed using a 19-nucleotide
sequence (gcgcgctttgtaggattcg) with no significant hom-
ology to any mammalian gene sequence and therefore
serves as a non-silencing control (OligoEngine). These
sequences were inserted into the pSUPER.retro.circular.
stuffer backbone.
B16 cells, maintained in RPMI 1640 containing 10%
FCS, were plated onto 6-well plates at 2 × 105 cells per
well. After cultured in 37°C, 5%CO2 for 24 h, cells were
transfected with 4 μg of RNAi plasmid hybrids using Li-
pofectamine 2000 reagent (Invitrogen) according to the
manufacturer’s instructions. Stable transfected cell lines
were screened and selected with 0.5 μg/ml puromycin
(Sigma). Clonal cell lines were selected by Western blot-
ting to confirm lack or low expression of mBAP31.
Western blotting analysis
Cell lysates (20 μg) were separated by SDS-PAGE and
transferred onto Immobilon-P membrane (Millipore,
Billerica, MA). The membrane was then blocked with
5% skim milk in PBST (0.29% Na2HPO4, 0.8% NaCl,
0.02% KCl, and 0.05% Tween-20, pH7.4) for 1 h at
room temperature (RT) and then incubated with anti-
mBAP31 mAb (diluted to 5 μg/mL) or control mAb for
1 h at RT. After washing three times with PBST, the
membrane was incubated with HRP-conjugated goat
anti-mouse IgG (1:1500 v/v, Promega) for 1 h at RT.
Figure 1 Immunoperoxidase staining of human BAP31 in human
MMs. Representative expression patterns of BAP31 in human MMs
(A-C). The majority of tumor cells were intensely stained in the
cytoplasm. Normal mouse IgG was applied as negative control (D).
Bar: 50 μm.
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(GE Healthcare) and exposed to Agfa x-ray film. Anti-
β-actin mAb was used as internal standard for all
samples.
Construction of DNA vaccine encoding mBAP31
The p43 and p43-LAMP vectors were kind gifts of Dr.
August. Full length of mBAP31 was cloned, inserted into
the vectors and termed p-mBAP31 and p-LAMP/
mBAP31 respectively. The vaccination plasmids were
produced by transforming Escherichia coli DH5a, and
were then purified to remove endotoxin (Qiagen, Valencia,
CA, USA). These plasmids were also constructed to carry
enhanced green fluorescent protein (EGFP), p-mBAP31/
EGFP and p-LAMP/mBAP31/EGFP, for expedient analysis
of protein expression. EGFP-tagged protein expressions
were studied by transfecting them into 293 T cell lines.
EGFP expression was observed 24–48 h after transfection
by fluorescence microscopy.
Immunization and evaluation of DNA vaccine immune
response
Three groups female C57BL/6 mice were immunized
subcutaneously at the base of the tail with 50 μg of the spe-
cified endotoxin-free DNA plasmid (p-mBAP31, p-LAMP/
mBAP31) diluted in phosphate-buffered saline (PBS) or
PBS as negative control. The mice were boosted twice every
3 weeks with the same plasmid. Immunized mice were
observed of clinical manifestation of autoimmune diseases
such as weight loss, hair/skin disorders, diarrhea or neuro-
logical disorders. 2 weeks after the third DNA injection, the
frequency of cells producing IFN-γ in splenocytes was
measured by ELISPOT. In briefly, Single cell suspensions
depleted of red blood cells were prepared from freshly
isolated immunized mouse splenocytes and washed 2 times
with RPMI 1640 and then resuspended in RPMI 1640
contained 10% FBS. BAP31 specific IFN-γ production was
determined by a standard ELISPOT assay following a 24 h
incubation of splenocytes (106 per well) with synthetic over-
lapping mBAP31 peptides (1 μg/mL, 15-mer peptides span-
ning the mBAP31 protein, each overlapping the next by 9
amino acids). As a negative control, splenocytes cells were
pulsed with the irrelevant 15-mer peptide of Hantaan virus
(QTADWLSIIVYLTSF). ConA and recombinant mBAP31
(1 μg/mL) were used as positive controls.
Cytotoxcity assay
Cytoxicity of CTLs of immunized mice was determined
by quantitative measurements of the release of lactic
dehydrogenase (LDH). The mouse melanoma B16 cells
(H-2b), colon carcinoma CT26 cells (H-2d) or 2E8 cells
(mBAP31-depleted B16 cells) were pulsed with or without
corresponding peptides (2 μg/mL) and used as target cells.
CD8+ cells, isolated from splenocytes of immunizedC57BL/6 mice by magnetic beads conjugated with anti-
CD8 mAbs (BD pharmingen), served as effector cells.
CTL assays were performed with effector cells (E) and
target cells (T) (1 × 104 cells/well) mixed together at
ratios of 50:1, 25:1 or 12.5:1 in a final volume of 100 μl.
After 4 h incubation at 37°C, 50 μl of the cultured su-
pernatants was collected to assess the amount of LDH
release using Non-Radioactive Cytotoxicity Assay kits
(Promega). The percentage of target cell lysis was cal-
culated from the following equation: 100 × (A-B)/(C-D),
where A is the reading value of experimental signal, B
is spontaneous background signal value of the effector
cells, C is maximum signal value from target cells, and
D is spontaneous background signal value of the target
cells.
Therapeutic anti-tumor model of mBAP31 DNA vaccine in
C57BL/6 mouse
C57BL/6 mice were transplanted subcutaneously with
5 × 104 B16 cells per mouse at day 0. On day 3, mice
were randomized and divided into three groups (n = 8),
immunized subcutaneously at the base of the tail with
50 μg of the DNA plasmid (p-mBAP31, p-LAMP/
mBAP31) and PBS as negative control. Vaccination was
repeated on days 10, 17, and 24 with the same plasmid.
Tumor dimensions were measured serially, and tumor
volumes were calculated using the following formula:
long axis × (short axis)2 × 0.52 [17]. On day 42, B16 melan-
oma tumor bearing mice from each group were sacrificed
and the tumors were removed from the mice.
Statistical analysis
Differences of IFN-γ production in ELISPOT assays and
tumor volumes in tumor therapeutic model in C57BL/6
Figure 2 Expression profiles of human BAP31 in normal human tissues analyzed by IHC staining. There was marginal immunoreactivity for BAP31
in the lung (A), colon (B) and rectum (C). The brown products in these tissues were restricted to minority of cells. Whereas the skin (D) ovary (E),
breast (F), cervix (G) and esophagus (H) were negative for BAP31. Bar: 50 μm.
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two tailed and all statistical analyses used SPSS 17.0
software. Differences at P < 0.05 were considered statis-
tically significant.
Results
Protein expression profiles of hBAP31 in human MMs
To assess the protein expression levels of hBAP31 in
MMs, we employed IHC analysis using mAbs against
hBAP31 established in our lab [18]. Of 141 MMs, 122
cases (86.5%) were hBAP31 positive. Representative
expression patterns of hBAP31 in MMs were shown in
Figure 1. The majority of tumor cells were intensely
stained in the cytoplasm.
Protein expression profiles of hBAP31 in human normal
tissues
Previous studies had shown that hBAP31 protein expres-
sion is restricted to a minority of cells in normal human
tissues analyzed by immunohistochemistry [14]. The pro-
tein expression profiles of hBAP31 in human normal tis-
sues in our study were consistent with previous report. InFigure 3 Expression profiles of mBAP31 in normal mouse tissues. We perfo
important organs of C57BL/6 mice. BAP31 reactivity was not found in mou
kidney (G). Strong positive products were restricted to minority of mouse sthis experiment, all negative controls showed no specific
positive reaction. Prominent hBAP31 protein expression
analyzed by IHC staining in this study is restricted to a mi-
nority of cells in lung, colon and rectum. hBAP31 protein
expression was negative in skin, ovary, breast, cervix and
esophagus (Figure 2).
Protein expression profiles of mBAP31 in mouse normal
tissues
Although northern blotting analyses have revealed that
mBAP31 RNA transcripts are ubiquitously expressed
[13], there are no data on the mBAP31 protein expression
profiles of mouse normal tissues. Using the mAbs against
mBAP31 generated in our lab, we performed IHC staining
to investigate the protein expression of mBAP31 in im-
portant organs of C57BL/6 mice. mBAP31 reactivity was
not found in mouse brain, skin, colon, lung, liver, pancreas
or kidney. Strong positive products were only found in
minority of mouse splenocytes (Figure 3). The mechanism
of the discrepancy of the expression level between the
mRNA and protein of hBAP31 and mBAP31 should be
investigated more intensely. Moreover, western blotrmed IHC staining to investigate the protein expression of mBAP31 in
se brain (A), skin (B), colon (C), lung (D), liver (E), pancreas (F) or
plenocytes (H). Bar: 50 μm.
Figure 4 (See legend on next page.)
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Figure 4 Induction of mBAP31-specific IFN-γ production by T cells following mBAP31 DNA vaccine vaccination in C57BL/6 mice. Three groups (n = 6) of
female C57BL/6 mice were immunized subcutaneously at the base of the tail with the specified DNA plasmid (p-mBAP31, p-LAMP/mBAP31) or PBS and
were boosted twice every 3 weeks. 2 weeks after the third vaccination, mice were sacrificed and the splenocytes were harvested. The frequency of cells
producing IFN-γ in splenocytes was measured by ELISPOT. The number of IFN-γ-producing cells of p-LAMP/mBAP31 group was significantly higher than
that of p-mBAP31 and control group.
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files of mBAP31 in mouse normal tissues (Additional
file 1: Figure S1).
Expression of mBAP31 protein in B16 cells, CT26 cells and
siRNA B16 cells
Western blot analysis was performed to determine the
expression profiles of mBAP31 protein in B16 cells,
CT26 cells and siRNA B16 cells. As shown in Additional
file 2: Figure S2, there is a special 28KD band in the film
suggesting high protein expression of mBAP31 in B16
cells and CT26 cells. B16 cells were then transfected
with the pSUPER-mBAP31 or pSUPER-Control, and se-
lected with puromycin for 3 weeks. The pSUPER-BAP31
and pSUPER-Control cells were cloned and analyzed
BAP31 expression by Western blot. One pSUPER-
mBAP31-transfected clonal cell line named 2E8 with a
remarkable reduction in mBAP31 protein expression
was obtained after cultured for 2 months compared with
the pSUPER-Control transfected clonal cell line 1H12
and non-transfected B16 cells. Anti-β-actin mAb was
used as internal standard for all samples.
Expression of mBAP31 protein in mBAP31 DNA vaccine
transfected cells
The mBAP31 DNA vaccine was constructed with mouse
homologue. The DNA vaccine must be able to express
in mammalian cells for subsequent processing and pres-
entation to T cells. To evaluate the expression levels of
DNA vaccine vectors in mammalian cells, plasmids of
EGFP-tagged mBAP31 and LAMP/mBAP31 were trans-
fected into 293 T cells. The expression levels were ana-
lyzed by fluorescence microscopy and no significant
difference in the fluorescence intensity of the transfected
cells was observed, suggesting similar synthesis and
translation rates for the two EGFP-tagged molecules
(Additional file 3: Figure S3).
Vaccination with mBAP31 DNA vaccine could elicit high
level of cellular immune responses in C57BL/6 mice
Three groups of female C57BL/6 mice were immunized
subcutaneously at the base of the tail with the specified
DNA plasmid (p-mBAP31, p-LAMP/mBAP31, PBS as
negative control) and were boosted twice every 3 weeks
with the same plasmid. Immunized mice exhibited no
clinical manifestation of autoimmune diseases such as
weight loss, hair/skin disorders, diarrhea or neurologicaldisorders. 2 weeks after the third DNA injection, the
frequency of cells producing IFN-γ in splenocytes was
measured by ELISPOT. The results of ELISPOT
showed that T cell responses to mBAP31 were detected
after three immunizations and the number of IFN-γ-
producing cells of p-LAMP/mBAP31 group was signifi-
cantly higher than that of p-mBAP31 and control group
(Figure 4, P < 0.05), indicating that vaccination with
mBAP31 DNA vaccine, especially LAMP chimera
mBAP31 DNA vaccine, stimulated the expansion of
mBAP31-specific T cells.
Vaccination with mBAP31 DNA vaccine elicits
mBAP31-specific cytotoxic T cells
Cytoxicity of CTLs of immunized mice was determined
by quantitative measurements of the release of LDH.
The mouse melanoma B16 cells (H-2b), colon carcinoma
CT26 cells (H-2d) or 2E8 cells (mBAP31-depleted B16
cells) were pulsed with or without corresponding pep-
tides (2 μg/mL) and used as target cells. CD8+ cells were
isolated from splenocytes of immunized C57BL/6 mice
by magnetic beads conjugated with anti-CD8 mAbs and
served as effector cells. The CD8+ cells from both p-
mBAP31 and p-LAMP/mBAP31 immunized mice could
efficiently kill B16 cells, mBAP31 peptides pulsed 2E8 cells
but not 2E8 cells without pulsing mBAP31 peptides,
CT26 cells (pulsed with or without mBAP31 peptides) at
50:1 ratio. And LAMP molecule could significantly en-
hance the cytotoxicity of mBAP31-specific CTLs against
B16 cells (Figure 5). Thus, mBAP31 DNA vaccine could
effectively induce anti-mBAP31 CTLs with anti-tumor
activity.
Vaccination with mBAP31 DNA vaccine suppresses tumor
growth in a therapeutic model
The ability of therapeutic anti-tumor effects in tumor-
bearing mice of mBAP31 DNA vaccine was investigated
using mBAP31-positive B16 melanoma cells in C57BL/6
mice. C57BL/6 mice were transplanted subcutaneously
with 5 × 104 B16 cells per mouse at day 0, and were im-
munized with p-mBAP31, p-LAMP/mBAP31 or PBS on
days 3, 10, 17 and 24. Tumor size was measured every
week from day 0 and all mice were sacrificed on day 42.
As shown in Figure 6, vaccination with p-mBAP31 and
p-LAMP/mBAP31 could significantly inhibited the B16
tumor growth compared with PBS group (P < 0.05).
Moreover, p-LAMP/mBAP31 vaccine had much better
Figure 5 LDH release assay for cytotoxicity of CTLs from mBAP31 vaccinated mice against murine cancer cell lines. Cytotoxic activities of CTLs
isolated from the splenocytes of the p-LAMP/mBAP31 vaccinated C57BL/6 mice (H-2b) against mBAP31 peptides pulsed mouse colon cancer cell
lines CT26 (H-2d), 2E8 (mBAP31 depleted B16 cells, H-2b) and B16 (H-2b) were detected by LDH release assay at effector-to-target ratio of 50:1.
Peptides used were indicated in abscissa (A-C). Cytotoxic activities of CTLs from p-LAMP/mBAP31 (△), p-mBAP31 (□) or PBS (○) vaccinated C57BL/6
mice (H-2b) against B16 cells pulsed with mBAP31149–157 expressing both H-2
b and mBAP31 (D), 2E8 cells (mBAP31 depleted B16 cells) pulsed with
mBAP31149–157 expressing H-2
b but much lower mBAP31 than B16 cells (E), CT26 cells pulsed with mBAP31149–157 expressing H-2
d and mBAP31 (F),
B16 cells expressing both H-2b and mBAP31 (G), 2E8 cells expressing H-2b but much lower mBAP31 than B16 cells (H) and CT26 cells expressing H-2d
and mBAP31 (I).
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These data suggested that the LAMP/mBAP31 vaccine has
potent anti-tumor activity even in the established tumor.Furthermore, tumor-bearing mice treated with p-LAMP/
mBAP31 vaccine resulting in increased infiltration of CD8+
T cells into MM tissues (Additional file 4: Figure S4).
Figure 6 Suppression of tumor growth following mBAP31 DNA
vaccine vaccinations in B16 melanoma-bearing C57BL/6 mice. C57BL/6
mice were transplanted subcutaneously with 5 × 104 B16 cells per
mouse at day 0, and were immunized with p-mBAP31, p-LAMP/
mBAP31 or PBS on days 3, 10, 17 and 24. Tumor size was serially
measured and mice were sacrificed on day 42. Student t test was
done based on the data of day 42. *, P < 0.05 for the comparison
of the tumor volume between the p-LAMP/mBAP31 vaccinated
mice and those vaccinated with p-mBAP31 or PBS. **, P < 0.05 for
the comparison between the p-mBAP31 vaccinated mice and
those vaccinated with PBS.
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For the first time, we found that protein expression of
hBAP31 were dramatically upregulated in human MM
tissues when compared with human normal tissues (lung,
colon, rectum, liver, ovary, breast, cervix and esophagus),
with a total positive rate of 86.5% (122 of 141 cases). And
predominant protein expression of mBAP31 was found in
mouse B16 melanoma cells but not in mouse important
organs including brain, heart, colon, lung, liver, pancreas
and kidney. Northern blotting analyses have revealed that
BAP31 RNA transcripts are ubiquitously expressed, but
prominent BAP31 protein expression analyzed by immu-
nohistochemistry in our study and previous reports is
restricted to a minority of cells in normal human tissues
although its RNA transcripts are ubiquitously expressed
[13,14]. The mechanism of the discrepancy of the expres-
sion level between the mRNA and protein of BAP31
should be investigated more intensely.
For a tumor antigen to be a promising immunothera-
peutic target, the following properties would be crucial:
1) the protein expression should be documented by IHC
analysis, and 2) the gene should have a reasonable
frequency of expression, ideally in at least 10-20% of at
least one or two tumor types [19]. Using these two
criteria, we have evaluated the BAP31, a gene product
encoded by a gene located on Xq26, was hypothesized
in the present study as a promisingly attractive vaccine
target for human MMs.The past five decades have witnessed a steady increase
in the incidence of MMs [20]. While early detection,
appropriate surgery and, in some cases, adjuvant therapy
have improved outcomes, at least one third of patients
with early-stage melanoma will develop metastases. The
prognosis for patients with metastatic melanoma re-
mains dismal. Studies have shown that biochemotherapy
(chemotherapy combined with interleukin-2 and inter-
feron) was not associated with a statistically significant
survival benefit in any of the individual trials or in a
pooled analysis [21-26]. The emerging field of cancer
immunotherapy offers a number of exciting promising
treatments and cast new light on the therapeutic strat-
egies of the disease [5,27-32].
Currently, cancer vaccine therapy for MMs has a 2-fold
focus. On the one hand, advances have been aimed at
improving the effectiveness of MM vaccines based on the
identification of various MM associated antigens (i.e.,
MAGE, GAGE, SPANXC, SSX, etc.) [33-40]. On the other
hand, the immune system also inadvertently plays a sup-
portive role in promoting the development and progression
of tumors [21,41]. Because tumor cells have multiple mech-
anisms to escape the cytotoxicity of the immune system,
polyvalent vaccines are desirable, prompting searches for
novel MM associated antigens.
BAP31 is an endoplasmic reticulum protein-sorting
factor that associates with newly synthesized integral
membrane proteins and controls their fate (i.e., egress,
retention, survival, or degradation). For the first time, we
identified high protein expression level of hBAP31 in
human MM tissues, with a total positive rate of 86.5%.
These results suggested that hBAP31 might be a promis-
ingly attractive vaccine target for human MMs.. Moreover,
our preliminary work suggested that depletion of BAP31
has a negative impact on the proliferation of tumor cells,
indicating that BAP31 may play an important role in
tumorigenesis. Further experiments showed that BAP31
might facilitate the resistance to apoptosis triggered by mul-
tiple chemotherapeutic drugs including cisplatin, VP-16
and taxol in vitro, which was used for the adjuvant chemo-
therapy various cancers (unpublished data).
To enhance the immune response against mBAP31
DNA vaccines, we developed a LAMP-mBAP31 chimera
DNA vaccine based on previous reports on its function
of enhancing T cell responses against various virus and
tumor antigens. When C57BL/6 mice were immunized
with LAMP-mBAP31 chimera DNA vaccine, stronger cel-
lular response to mBAP31, CTL cytotoxicity and anti-
tumor effects in the therapeutic model were observed than
mice vaccinated with p-mBAP31 DNA vaccine. Moreover,
no autoimmune disorders were observed in the vaccinated
mice, suggesting the safety of vaccination with mBAP31
DNA vaccine. These are the first data supporting a vaccine
targeting BAP31 that will be applicable to human MMs.
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with a novel LAMP-mBAP31 chimera DNA vaccine can
successfully generate mBAP31-specific anti-tumor im-
munity in mice supports further evaluation regarding
the promising clinical efficacy of this vaccine and the
preclinical trials is ongoing in our lab.
Additional files
Additional file 1: Figure S1. Expression of mBAP31 protein in normal
mouse tissues detected by Western blot. Western blot analysis was
performed to determine the expression profiles of mBAP31 protein in
colon (Lane 1), lung (Lane 2), liver (Lane 3), spleen (Lane 4), skin (Lane 5)
and kidney (Lane 6). There are no significant 28KD bands in the film,
suggesting low protein expression of mBAP31 in mouse normal tissues
mentioned above. Anti-β-actin mAb was used as internal standard for all
samples.
Additional file 2: Figure S2. Expression of mBAP31 protein in B16 cells,
CT26 cells and siRNA B16 cells detected by Western blot. Western blot
analysis was performed to determine the expression profiles of mBAP31
protein in B16 cells (Lane 1), 1H12 cells (Lane 2, pSUPER-Control-
transfected clonal cell line,), 2E8 cells (Lane 3, pSUPER-mBAP31-
transfected clonal cell line) and CT26 cells (Lane 4). There is a special
28KD band in the film suggesting high protein expression of mBAP31 in
B16 cells, 1H12 cells and CT26 cells. Expression of mBAP31 was significantly
down-regulated in 2E8 cells. Anti-β-actin mAb was used as internal standard
for all samples.
Additional file 3: Figure S3. Expression of mBAP31 protein in mBAP31
DNA vaccine transfected cells. No significant difference in the
fluorescence intensity of the levels of EGFP-tagged mBAP31 (A) and
LAMP/mBAP31 (B) expression in transfected 293T cells when analyzed by
fluorescence microscopy.
Additional file 4: Figure S4. Increased infiltration CD8+ T cells into MM
tissues of tumor-bearing mice treated with p-LAMP/mBAP31. To obtain
tumor infiltrated lymphocytes (TIL), tumor grafts were cut into small pieces
and digested with collagenase and DNase I followed by Ficoll-Hypaque
separation. Then the TILs were incubated with FITC-labeled anti-CD8
mAb and analyzed by flow cytometry. The infiltration levels of TILs in
tumor-bearing animals treated with p-LAMP/mBAP31 (C) showed a
higher degree of CD8+ T cell infiltration into the tumor tissues than
animals treated with p-mBAP31 (B) or PBS (A).
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